Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Vericel Corporation is a biotechnology business based in the US. Vericel Corporation shares (VCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Vericel Corporation employs 273 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $33.60 |
|---|---|
| 52-week range | $31.38 - $68.94 |
| 50-day moving average | $38.71 |
| 200-day moving average | $49.71 |
| Wall St. target price | $53.96 |
| PE ratio | 6786 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.01 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $33.6 from 2022-01-25
| 1 week (2022-01-15) | N/A |
|---|---|
| 1 month (2021-12-22) | -16.98% |
| 3 months (2021-10-26) | -33.88% |
| 6 months (2021-07-26) | -34.93% |
| 1 year (2021-01-26) | -17.75% |
|---|---|
| 2 years (2020-01-24) | 99.76% |
| 3 years (2019-01-25) | 94.22% |
| 5 years (2017-01-26) | 1,167.92% |
Valuing Vericel Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vericel Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vericel Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6786x. In other words, Vericel Corporation shares trade at around 6786x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Vericel Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.1 million.
The EBITDA is a measure of a Vericel Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $153.8 million |
|---|---|
| Operating margin TTM | 0.19% |
| Gross profit TTM | $84.2 million |
| Return on assets TTM | 0.1% |
| Return on equity TTM | 0.16% |
| Profit margin | 0.14% |
| Book value | $3.35 |
| Market capitalisation | $1.6 billion |
TTM: trailing 12 months
We're not expecting Vericel Corporation to pay a dividend over the next 12 months.
Vericel Corporation's shares were split on a 1:20 basis on 15 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vericel Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Vericel Corporation shares which in turn could have impacted Vericel Corporation's share price.
Over the last 12 months, Vericel Corporation's shares have ranged in value from as little as $31.3793 up to $68.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vericel Corporation's is 1.9681. This would suggest that Vericel Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. .
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.